{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107780","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.596374+00:00","generated_at":"2026-05-16T23:38:42.994909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coherus Q3 LOQTORZI rev up 92% YoY to $11.2M; net loss narrows to $44.5M; CHS-114 enters colorectal cancer","bullets":["Net revenue $11.6M (up 90% YoY); LOQTORZI net revenue $11.2M (+12% QoQ, +92% YoY).","GAAP net loss from continuing ops $44.5M (-$0.38/sh) vs $47.6M (-$0.41/sh) prior year.","Non-GAAP net loss $38.9M (-$0.33/sh) vs $40.0M (-$0.35/sh); cash at $191.7M.","CHS-114 Phase 1b/2a enrolling in 4L+ colorectal cancer; initial data expected 2H 2026.","Casdozokitug Phase 2 in 1L HCC enrollment ongoing; first data readout mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107780","json":"https://secwatch.observer/filing/0001104659-25-107780.json","markdown":"https://secwatch.observer/filing/0001104659-25-107780.md","text":"https://secwatch.observer/filing/0001104659-25-107780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/0001104659-25-107780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:38:42.994909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}